Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 1, 2008

Primary Completion Date

July 1, 2012

Study Completion Date

July 1, 2012

Conditions
MDSAMLSolid TumorsMultiple MyelomaNon-Hodgkin's LymphomaHodgkin's Disease
Interventions
DRUG

azacitidine

Trial Locations (11)

10461

Montefiore Medical Center, The Bronx

30912

MCG Cancer Center, Augusta

33012

Palm Springs Research Institute, Hialeah

40536

University of Kentucky-Markey Cancer Center Clinical Research Organization, Lexington

44718

Gabrail Cancer Center, Canton

58501

Mid Dakota Clinical P.C. - Cancer Treatment and Research Center, Bismarck

60435

Joliet Oncology-Hematology Associates, Ltd., Joliet

78229

Cancer Therapy and Research Center, San Antonio

89135

Nevada Cancer Institute, Las Vegas

94704

Sutter East Bay Hospitals, Berkeley

02915

Pharma Resource, East Providence

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT00652626 - Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function | Biotech Hunter | Biotech Hunter